Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination
There is still considerable controversy in the literature regarding the capacity of intramuscular messenger RNA (mRNA) vaccination to induce a mucosal immune response. To compare serum and salivary IgG and IgA levels among mRNA-vaccinated individuals with or without previous SARS-CoV-2 infection. In...
Gespeichert in:
| Veröffentlicht in: | JAMA network open 2024-04, Vol.7 (4), p.e248051 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | e248051 |
| container_title | JAMA network open |
| container_volume | 7 |
| creator | Gorochov, Guy Ropers, Jacques Launay, Odile Dorgham, Karim da Mata-Jardin, Omaira Lebbah, Said Durier, Christine Bauer, Rebecca Radenne, Anne Desaint, Corinne Vieillard, Louis-Victorien Rekacewicz, Claire Lachatre, Marie Parfait, Béatrice Batteux, Frédéric Hupé, Philippe Ninove, Läétitia Lefebvre, Maeva Conrad, Anne Dussol, Bertrand Maakaroun-Vermesse, Zoha Melica, Giovanna Nicolas, Jean-François Verdon, Renaud Kiladjian, Jean-Jacques Loubet, Paul Schmidt-Mutter, Catherine Dualé, Christian Ansart, Séverine Botelho-Nevers, Elisabeth Lelièvre, Jean-Daniel de Lamballerie, Xavier Kieny, Marie-Paule Tartour, Eric Paul, Stéphane |
| description | There is still considerable controversy in the literature regarding the capacity of intramuscular messenger RNA (mRNA) vaccination to induce a mucosal immune response.
To compare serum and salivary IgG and IgA levels among mRNA-vaccinated individuals with or without previous SARS-CoV-2 infection.
In this cohort study, SARS-CoV-2-naive participants and those with previous infection were consecutively included in the CoviCompare P and CoviCompare M mRNA vaccination trials and followed up to day 180 after vaccination with either the BNT162b2 (Pfizer-BioNTech) vaccine or the mRNA-1273 (Moderna) vaccine at the beginning of the COVID-19 vaccination campaign (from February 19 to June 8, 2021) in France. Data were analyzed from October 25, 2022, to July 13, 2023.
An ultrasensitive digital enzyme-linked immunosorbent assay was used for the comparison of SARS-CoV-2 spike-specific serum and salivary IgG and IgA levels. Spike-specific secretory IgA level was also quantified at selected times.
A total of 427 individuals were included in 3 groups: participants with SARS-CoV-2 prior to vaccination who received 1 single dose of BNT162b2 (Pfizer-BioNTech) (n = 120) and SARS-CoV-2-naive individuals who received 2 doses of mRNA-1273 (Moderna) (n = 172) or 2 doses of BNT162b2 (Pfizer-BioNTech) (n = 135). The median age was 68 (IQR, 39-75) years, and 228 (53.4%) were men. SARS-CoV-2 spike-specific IgG saliva levels increased after 1 or 2 vaccine injections in individuals with previous infection and SARS-CoV-2-naive individuals. After vaccination, SARS-CoV-2-specific saliva IgA levels, normalized with respect to total IgA levels, were significantly higher in participants with previous infection, as compared with the most responsive mRNA-1273 (Moderna) recipients (median normalized levels, 155 × 10-5 vs 37 × 10-5 at day 29; 107 × 10-5 vs 54 × 10-5 at day 57; and 104 × 10-5 vs 70 × 10-5 at day 180 [P |
| doi_str_mv | 10.1001/jamanetworkopen.2024.8051 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11040412</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3141378304</sourcerecordid><originalsourceid>FETCH-LOGICAL-c486t-89ef321fa30b834975c6b06a3d021c2be82c26eb144735f001628ea3d3a657143</originalsourceid><addsrcrecordid>eNpdUVFv0zAYtBCITWN_AQXxAg8p32c7jvOEogJbpcLQBnu1HNfpUhK72EkR_x6Xjmn0yfZ9d2efj5BXCDMEwHcbPWhnx18-_PBb62YUKJ9JKPAJOaVFyXOWDk8f7U_IeYwbAKCArBLFc3LCpCgoL_GUfL2xYRoy7VbZje67nQ6_s8X64i-wWNfZtY1b76LN6na0IZtf3S4-5Fhln22M1q0TdP2lzm61MZ3TY-fdC_Ks1X205_frGfn-6eO3-WW-vLpYzOtlbrgUYy4r2zKKrWbQSMarsjCiAaHZCiga2lhJDRW2Qc5LVrQpuKDSpjHToiiRszPy_uC7nZrBrox1Y9C92oZuSBmU1536f-K6O7X2O4UIHDjS5PD24HB3pLusl2qPAReiQlruMHHf3N8W_M_JxlENXTS271MVfoqKAS8QJRWQqK-PqBs_BZf-QjHkyEqZyIlVHVgm-BiDbR9egKD2PaujntW-Z7XvOWlfPo7-oPzXKvsD6VqlMQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3141378304</pqid></control><display><type>article</type><title>Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Gorochov, Guy ; Ropers, Jacques ; Launay, Odile ; Dorgham, Karim ; da Mata-Jardin, Omaira ; Lebbah, Said ; Durier, Christine ; Bauer, Rebecca ; Radenne, Anne ; Desaint, Corinne ; Vieillard, Louis-Victorien ; Rekacewicz, Claire ; Lachatre, Marie ; Parfait, Béatrice ; Batteux, Frédéric ; Hupé, Philippe ; Ninove, Läétitia ; Lefebvre, Maeva ; Conrad, Anne ; Dussol, Bertrand ; Maakaroun-Vermesse, Zoha ; Melica, Giovanna ; Nicolas, Jean-François ; Verdon, Renaud ; Kiladjian, Jean-Jacques ; Loubet, Paul ; Schmidt-Mutter, Catherine ; Dualé, Christian ; Ansart, Séverine ; Botelho-Nevers, Elisabeth ; Lelièvre, Jean-Daniel ; de Lamballerie, Xavier ; Kieny, Marie-Paule ; Tartour, Eric ; Paul, Stéphane</creator><creatorcontrib>Gorochov, Guy ; Ropers, Jacques ; Launay, Odile ; Dorgham, Karim ; da Mata-Jardin, Omaira ; Lebbah, Said ; Durier, Christine ; Bauer, Rebecca ; Radenne, Anne ; Desaint, Corinne ; Vieillard, Louis-Victorien ; Rekacewicz, Claire ; Lachatre, Marie ; Parfait, Béatrice ; Batteux, Frédéric ; Hupé, Philippe ; Ninove, Läétitia ; Lefebvre, Maeva ; Conrad, Anne ; Dussol, Bertrand ; Maakaroun-Vermesse, Zoha ; Melica, Giovanna ; Nicolas, Jean-François ; Verdon, Renaud ; Kiladjian, Jean-Jacques ; Loubet, Paul ; Schmidt-Mutter, Catherine ; Dualé, Christian ; Ansart, Séverine ; Botelho-Nevers, Elisabeth ; Lelièvre, Jean-Daniel ; de Lamballerie, Xavier ; Kieny, Marie-Paule ; Tartour, Eric ; Paul, Stéphane</creatorcontrib><description>There is still considerable controversy in the literature regarding the capacity of intramuscular messenger RNA (mRNA) vaccination to induce a mucosal immune response.
To compare serum and salivary IgG and IgA levels among mRNA-vaccinated individuals with or without previous SARS-CoV-2 infection.
In this cohort study, SARS-CoV-2-naive participants and those with previous infection were consecutively included in the CoviCompare P and CoviCompare M mRNA vaccination trials and followed up to day 180 after vaccination with either the BNT162b2 (Pfizer-BioNTech) vaccine or the mRNA-1273 (Moderna) vaccine at the beginning of the COVID-19 vaccination campaign (from February 19 to June 8, 2021) in France. Data were analyzed from October 25, 2022, to July 13, 2023.
An ultrasensitive digital enzyme-linked immunosorbent assay was used for the comparison of SARS-CoV-2 spike-specific serum and salivary IgG and IgA levels. Spike-specific secretory IgA level was also quantified at selected times.
A total of 427 individuals were included in 3 groups: participants with SARS-CoV-2 prior to vaccination who received 1 single dose of BNT162b2 (Pfizer-BioNTech) (n = 120) and SARS-CoV-2-naive individuals who received 2 doses of mRNA-1273 (Moderna) (n = 172) or 2 doses of BNT162b2 (Pfizer-BioNTech) (n = 135). The median age was 68 (IQR, 39-75) years, and 228 (53.4%) were men. SARS-CoV-2 spike-specific IgG saliva levels increased after 1 or 2 vaccine injections in individuals with previous infection and SARS-CoV-2-naive individuals. After vaccination, SARS-CoV-2-specific saliva IgA levels, normalized with respect to total IgA levels, were significantly higher in participants with previous infection, as compared with the most responsive mRNA-1273 (Moderna) recipients (median normalized levels, 155 × 10-5 vs 37 × 10-5 at day 29; 107 × 10-5 vs 54 × 10-5 at day 57; and 104 × 10-5 vs 70 × 10-5 at day 180 [P < .001]). In contrast, compared with day 1, spike-specific IgA levels in the BNT162b2-vaccinated SARS-CoV-2-naive group increased only at day 57 (36 × 10-5 vs 49 × 10-5 [P = .01]). Bona fide multimeric secretory IgA levels were significantly higher in individuals with previous infection compared with SARS-CoV-2-naive individuals after 2 antigenic stimulations (median optical density, 0.36 [IQR, 0.16-0.63] vs 0.16 [IQR, 0.10-0.22]; P < .001).
The findings of this cohort study suggest that mRNA vaccination was associated with mucosal immunity in individuals without prior SARS-CoV-2 infection, but at much lower levels than in previously infected individuals. Further studies are needed to determine the association between specific saliva IgA levels and prevention of infection or transmission.</description><identifier>ISSN: 2574-3805</identifier><identifier>EISSN: 2574-3805</identifier><identifier>DOI: 10.1001/jamanetworkopen.2024.8051</identifier><identifier>PMID: 38652471</identifier><language>eng</language><publisher>United States: American Medical Association</publisher><subject>2019-nCoV Vaccine mRNA-1273 ; Adult ; Aged ; Antibodies, Viral - analysis ; Antibodies, Viral - blood ; BNT162 Vaccine ; Cohort analysis ; Cohort Studies ; COVID-19 - immunology ; COVID-19 - prevention & control ; COVID-19 vaccines ; COVID-19 Vaccines - administration & dosage ; COVID-19 Vaccines - immunology ; Disease transmission ; Emerging diseases ; Female ; France ; Human health and pathology ; Humans ; Immunity, Mucosal - immunology ; Immunoglobulin A - analysis ; Immunoglobulin A - blood ; Immunoglobulin G - blood ; Immunology ; Infections ; Infectious diseases ; Life Sciences ; Male ; Middle Aged ; Online Only ; Original Investigation ; Saliva - immunology ; Santé publique et épidémiologie ; SARS-CoV-2 - immunology ; Severe acute respiratory syndrome coronavirus 2 ; Vaccination - methods ; Vaccinology</subject><ispartof>JAMA network open, 2024-04, Vol.7 (4), p.e248051</ispartof><rights>2024. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>Copyright 2024 Gorochov G et al. .</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c486t-89ef321fa30b834975c6b06a3d021c2be82c26eb144735f001628ea3d3a657143</citedby><cites>FETCH-LOGICAL-c486t-89ef321fa30b834975c6b06a3d021c2be82c26eb144735f001628ea3d3a657143</cites><orcidid>0000-0003-2097-9677 ; 0000-0002-8830-4273 ; 0000-0003-2773-7750 ; 0000-0002-8182-3628</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,860,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38652471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04669127$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Gorochov, Guy</creatorcontrib><creatorcontrib>Ropers, Jacques</creatorcontrib><creatorcontrib>Launay, Odile</creatorcontrib><creatorcontrib>Dorgham, Karim</creatorcontrib><creatorcontrib>da Mata-Jardin, Omaira</creatorcontrib><creatorcontrib>Lebbah, Said</creatorcontrib><creatorcontrib>Durier, Christine</creatorcontrib><creatorcontrib>Bauer, Rebecca</creatorcontrib><creatorcontrib>Radenne, Anne</creatorcontrib><creatorcontrib>Desaint, Corinne</creatorcontrib><creatorcontrib>Vieillard, Louis-Victorien</creatorcontrib><creatorcontrib>Rekacewicz, Claire</creatorcontrib><creatorcontrib>Lachatre, Marie</creatorcontrib><creatorcontrib>Parfait, Béatrice</creatorcontrib><creatorcontrib>Batteux, Frédéric</creatorcontrib><creatorcontrib>Hupé, Philippe</creatorcontrib><creatorcontrib>Ninove, Läétitia</creatorcontrib><creatorcontrib>Lefebvre, Maeva</creatorcontrib><creatorcontrib>Conrad, Anne</creatorcontrib><creatorcontrib>Dussol, Bertrand</creatorcontrib><creatorcontrib>Maakaroun-Vermesse, Zoha</creatorcontrib><creatorcontrib>Melica, Giovanna</creatorcontrib><creatorcontrib>Nicolas, Jean-François</creatorcontrib><creatorcontrib>Verdon, Renaud</creatorcontrib><creatorcontrib>Kiladjian, Jean-Jacques</creatorcontrib><creatorcontrib>Loubet, Paul</creatorcontrib><creatorcontrib>Schmidt-Mutter, Catherine</creatorcontrib><creatorcontrib>Dualé, Christian</creatorcontrib><creatorcontrib>Ansart, Séverine</creatorcontrib><creatorcontrib>Botelho-Nevers, Elisabeth</creatorcontrib><creatorcontrib>Lelièvre, Jean-Daniel</creatorcontrib><creatorcontrib>de Lamballerie, Xavier</creatorcontrib><creatorcontrib>Kieny, Marie-Paule</creatorcontrib><creatorcontrib>Tartour, Eric</creatorcontrib><creatorcontrib>Paul, Stéphane</creatorcontrib><title>Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination</title><title>JAMA network open</title><addtitle>JAMA Netw Open</addtitle><description>There is still considerable controversy in the literature regarding the capacity of intramuscular messenger RNA (mRNA) vaccination to induce a mucosal immune response.
To compare serum and salivary IgG and IgA levels among mRNA-vaccinated individuals with or without previous SARS-CoV-2 infection.
In this cohort study, SARS-CoV-2-naive participants and those with previous infection were consecutively included in the CoviCompare P and CoviCompare M mRNA vaccination trials and followed up to day 180 after vaccination with either the BNT162b2 (Pfizer-BioNTech) vaccine or the mRNA-1273 (Moderna) vaccine at the beginning of the COVID-19 vaccination campaign (from February 19 to June 8, 2021) in France. Data were analyzed from October 25, 2022, to July 13, 2023.
An ultrasensitive digital enzyme-linked immunosorbent assay was used for the comparison of SARS-CoV-2 spike-specific serum and salivary IgG and IgA levels. Spike-specific secretory IgA level was also quantified at selected times.
A total of 427 individuals were included in 3 groups: participants with SARS-CoV-2 prior to vaccination who received 1 single dose of BNT162b2 (Pfizer-BioNTech) (n = 120) and SARS-CoV-2-naive individuals who received 2 doses of mRNA-1273 (Moderna) (n = 172) or 2 doses of BNT162b2 (Pfizer-BioNTech) (n = 135). The median age was 68 (IQR, 39-75) years, and 228 (53.4%) were men. SARS-CoV-2 spike-specific IgG saliva levels increased after 1 or 2 vaccine injections in individuals with previous infection and SARS-CoV-2-naive individuals. After vaccination, SARS-CoV-2-specific saliva IgA levels, normalized with respect to total IgA levels, were significantly higher in participants with previous infection, as compared with the most responsive mRNA-1273 (Moderna) recipients (median normalized levels, 155 × 10-5 vs 37 × 10-5 at day 29; 107 × 10-5 vs 54 × 10-5 at day 57; and 104 × 10-5 vs 70 × 10-5 at day 180 [P < .001]). In contrast, compared with day 1, spike-specific IgA levels in the BNT162b2-vaccinated SARS-CoV-2-naive group increased only at day 57 (36 × 10-5 vs 49 × 10-5 [P = .01]). Bona fide multimeric secretory IgA levels were significantly higher in individuals with previous infection compared with SARS-CoV-2-naive individuals after 2 antigenic stimulations (median optical density, 0.36 [IQR, 0.16-0.63] vs 0.16 [IQR, 0.10-0.22]; P < .001).
The findings of this cohort study suggest that mRNA vaccination was associated with mucosal immunity in individuals without prior SARS-CoV-2 infection, but at much lower levels than in previously infected individuals. Further studies are needed to determine the association between specific saliva IgA levels and prevention of infection or transmission.</description><subject>2019-nCoV Vaccine mRNA-1273</subject><subject>Adult</subject><subject>Aged</subject><subject>Antibodies, Viral - analysis</subject><subject>Antibodies, Viral - blood</subject><subject>BNT162 Vaccine</subject><subject>Cohort analysis</subject><subject>Cohort Studies</subject><subject>COVID-19 - immunology</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 vaccines</subject><subject>COVID-19 Vaccines - administration & dosage</subject><subject>COVID-19 Vaccines - immunology</subject><subject>Disease transmission</subject><subject>Emerging diseases</subject><subject>Female</subject><subject>France</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Immunity, Mucosal - immunology</subject><subject>Immunoglobulin A - analysis</subject><subject>Immunoglobulin A - blood</subject><subject>Immunoglobulin G - blood</subject><subject>Immunology</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Online Only</subject><subject>Original Investigation</subject><subject>Saliva - immunology</subject><subject>Santé publique et épidémiologie</subject><subject>SARS-CoV-2 - immunology</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccination - methods</subject><subject>Vaccinology</subject><issn>2574-3805</issn><issn>2574-3805</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdUVFv0zAYtBCITWN_AQXxAg8p32c7jvOEogJbpcLQBnu1HNfpUhK72EkR_x6Xjmn0yfZ9d2efj5BXCDMEwHcbPWhnx18-_PBb62YUKJ9JKPAJOaVFyXOWDk8f7U_IeYwbAKCArBLFc3LCpCgoL_GUfL2xYRoy7VbZje67nQ6_s8X64i-wWNfZtY1b76LN6na0IZtf3S4-5Fhln22M1q0TdP2lzm61MZ3TY-fdC_Ks1X205_frGfn-6eO3-WW-vLpYzOtlbrgUYy4r2zKKrWbQSMarsjCiAaHZCiga2lhJDRW2Qc5LVrQpuKDSpjHToiiRszPy_uC7nZrBrox1Y9C92oZuSBmU1536f-K6O7X2O4UIHDjS5PD24HB3pLusl2qPAReiQlruMHHf3N8W_M_JxlENXTS271MVfoqKAS8QJRWQqK-PqBs_BZf-QjHkyEqZyIlVHVgm-BiDbR9egKD2PaujntW-Z7XvOWlfPo7-oPzXKvsD6VqlMQ</recordid><startdate>20240401</startdate><enddate>20240401</enddate><creator>Gorochov, Guy</creator><creator>Ropers, Jacques</creator><creator>Launay, Odile</creator><creator>Dorgham, Karim</creator><creator>da Mata-Jardin, Omaira</creator><creator>Lebbah, Said</creator><creator>Durier, Christine</creator><creator>Bauer, Rebecca</creator><creator>Radenne, Anne</creator><creator>Desaint, Corinne</creator><creator>Vieillard, Louis-Victorien</creator><creator>Rekacewicz, Claire</creator><creator>Lachatre, Marie</creator><creator>Parfait, Béatrice</creator><creator>Batteux, Frédéric</creator><creator>Hupé, Philippe</creator><creator>Ninove, Läétitia</creator><creator>Lefebvre, Maeva</creator><creator>Conrad, Anne</creator><creator>Dussol, Bertrand</creator><creator>Maakaroun-Vermesse, Zoha</creator><creator>Melica, Giovanna</creator><creator>Nicolas, Jean-François</creator><creator>Verdon, Renaud</creator><creator>Kiladjian, Jean-Jacques</creator><creator>Loubet, Paul</creator><creator>Schmidt-Mutter, Catherine</creator><creator>Dualé, Christian</creator><creator>Ansart, Séverine</creator><creator>Botelho-Nevers, Elisabeth</creator><creator>Lelièvre, Jean-Daniel</creator><creator>de Lamballerie, Xavier</creator><creator>Kieny, Marie-Paule</creator><creator>Tartour, Eric</creator><creator>Paul, Stéphane</creator><general>American Medical Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2097-9677</orcidid><orcidid>https://orcid.org/0000-0002-8830-4273</orcidid><orcidid>https://orcid.org/0000-0003-2773-7750</orcidid><orcidid>https://orcid.org/0000-0002-8182-3628</orcidid></search><sort><creationdate>20240401</creationdate><title>Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination</title><author>Gorochov, Guy ; Ropers, Jacques ; Launay, Odile ; Dorgham, Karim ; da Mata-Jardin, Omaira ; Lebbah, Said ; Durier, Christine ; Bauer, Rebecca ; Radenne, Anne ; Desaint, Corinne ; Vieillard, Louis-Victorien ; Rekacewicz, Claire ; Lachatre, Marie ; Parfait, Béatrice ; Batteux, Frédéric ; Hupé, Philippe ; Ninove, Läétitia ; Lefebvre, Maeva ; Conrad, Anne ; Dussol, Bertrand ; Maakaroun-Vermesse, Zoha ; Melica, Giovanna ; Nicolas, Jean-François ; Verdon, Renaud ; Kiladjian, Jean-Jacques ; Loubet, Paul ; Schmidt-Mutter, Catherine ; Dualé, Christian ; Ansart, Séverine ; Botelho-Nevers, Elisabeth ; Lelièvre, Jean-Daniel ; de Lamballerie, Xavier ; Kieny, Marie-Paule ; Tartour, Eric ; Paul, Stéphane</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c486t-89ef321fa30b834975c6b06a3d021c2be82c26eb144735f001628ea3d3a657143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>2019-nCoV Vaccine mRNA-1273</topic><topic>Adult</topic><topic>Aged</topic><topic>Antibodies, Viral - analysis</topic><topic>Antibodies, Viral - blood</topic><topic>BNT162 Vaccine</topic><topic>Cohort analysis</topic><topic>Cohort Studies</topic><topic>COVID-19 - immunology</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 vaccines</topic><topic>COVID-19 Vaccines - administration & dosage</topic><topic>COVID-19 Vaccines - immunology</topic><topic>Disease transmission</topic><topic>Emerging diseases</topic><topic>Female</topic><topic>France</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Immunity, Mucosal - immunology</topic><topic>Immunoglobulin A - analysis</topic><topic>Immunoglobulin A - blood</topic><topic>Immunoglobulin G - blood</topic><topic>Immunology</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Online Only</topic><topic>Original Investigation</topic><topic>Saliva - immunology</topic><topic>Santé publique et épidémiologie</topic><topic>SARS-CoV-2 - immunology</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccination - methods</topic><topic>Vaccinology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gorochov, Guy</creatorcontrib><creatorcontrib>Ropers, Jacques</creatorcontrib><creatorcontrib>Launay, Odile</creatorcontrib><creatorcontrib>Dorgham, Karim</creatorcontrib><creatorcontrib>da Mata-Jardin, Omaira</creatorcontrib><creatorcontrib>Lebbah, Said</creatorcontrib><creatorcontrib>Durier, Christine</creatorcontrib><creatorcontrib>Bauer, Rebecca</creatorcontrib><creatorcontrib>Radenne, Anne</creatorcontrib><creatorcontrib>Desaint, Corinne</creatorcontrib><creatorcontrib>Vieillard, Louis-Victorien</creatorcontrib><creatorcontrib>Rekacewicz, Claire</creatorcontrib><creatorcontrib>Lachatre, Marie</creatorcontrib><creatorcontrib>Parfait, Béatrice</creatorcontrib><creatorcontrib>Batteux, Frédéric</creatorcontrib><creatorcontrib>Hupé, Philippe</creatorcontrib><creatorcontrib>Ninove, Läétitia</creatorcontrib><creatorcontrib>Lefebvre, Maeva</creatorcontrib><creatorcontrib>Conrad, Anne</creatorcontrib><creatorcontrib>Dussol, Bertrand</creatorcontrib><creatorcontrib>Maakaroun-Vermesse, Zoha</creatorcontrib><creatorcontrib>Melica, Giovanna</creatorcontrib><creatorcontrib>Nicolas, Jean-François</creatorcontrib><creatorcontrib>Verdon, Renaud</creatorcontrib><creatorcontrib>Kiladjian, Jean-Jacques</creatorcontrib><creatorcontrib>Loubet, Paul</creatorcontrib><creatorcontrib>Schmidt-Mutter, Catherine</creatorcontrib><creatorcontrib>Dualé, Christian</creatorcontrib><creatorcontrib>Ansart, Séverine</creatorcontrib><creatorcontrib>Botelho-Nevers, Elisabeth</creatorcontrib><creatorcontrib>Lelièvre, Jean-Daniel</creatorcontrib><creatorcontrib>de Lamballerie, Xavier</creatorcontrib><creatorcontrib>Kieny, Marie-Paule</creatorcontrib><creatorcontrib>Tartour, Eric</creatorcontrib><creatorcontrib>Paul, Stéphane</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>JAMA network open</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gorochov, Guy</au><au>Ropers, Jacques</au><au>Launay, Odile</au><au>Dorgham, Karim</au><au>da Mata-Jardin, Omaira</au><au>Lebbah, Said</au><au>Durier, Christine</au><au>Bauer, Rebecca</au><au>Radenne, Anne</au><au>Desaint, Corinne</au><au>Vieillard, Louis-Victorien</au><au>Rekacewicz, Claire</au><au>Lachatre, Marie</au><au>Parfait, Béatrice</au><au>Batteux, Frédéric</au><au>Hupé, Philippe</au><au>Ninove, Läétitia</au><au>Lefebvre, Maeva</au><au>Conrad, Anne</au><au>Dussol, Bertrand</au><au>Maakaroun-Vermesse, Zoha</au><au>Melica, Giovanna</au><au>Nicolas, Jean-François</au><au>Verdon, Renaud</au><au>Kiladjian, Jean-Jacques</au><au>Loubet, Paul</au><au>Schmidt-Mutter, Catherine</au><au>Dualé, Christian</au><au>Ansart, Séverine</au><au>Botelho-Nevers, Elisabeth</au><au>Lelièvre, Jean-Daniel</au><au>de Lamballerie, Xavier</au><au>Kieny, Marie-Paule</au><au>Tartour, Eric</au><au>Paul, Stéphane</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination</atitle><jtitle>JAMA network open</jtitle><addtitle>JAMA Netw Open</addtitle><date>2024-04-01</date><risdate>2024</risdate><volume>7</volume><issue>4</issue><spage>e248051</spage><pages>e248051-</pages><issn>2574-3805</issn><eissn>2574-3805</eissn><abstract>There is still considerable controversy in the literature regarding the capacity of intramuscular messenger RNA (mRNA) vaccination to induce a mucosal immune response.
To compare serum and salivary IgG and IgA levels among mRNA-vaccinated individuals with or without previous SARS-CoV-2 infection.
In this cohort study, SARS-CoV-2-naive participants and those with previous infection were consecutively included in the CoviCompare P and CoviCompare M mRNA vaccination trials and followed up to day 180 after vaccination with either the BNT162b2 (Pfizer-BioNTech) vaccine or the mRNA-1273 (Moderna) vaccine at the beginning of the COVID-19 vaccination campaign (from February 19 to June 8, 2021) in France. Data were analyzed from October 25, 2022, to July 13, 2023.
An ultrasensitive digital enzyme-linked immunosorbent assay was used for the comparison of SARS-CoV-2 spike-specific serum and salivary IgG and IgA levels. Spike-specific secretory IgA level was also quantified at selected times.
A total of 427 individuals were included in 3 groups: participants with SARS-CoV-2 prior to vaccination who received 1 single dose of BNT162b2 (Pfizer-BioNTech) (n = 120) and SARS-CoV-2-naive individuals who received 2 doses of mRNA-1273 (Moderna) (n = 172) or 2 doses of BNT162b2 (Pfizer-BioNTech) (n = 135). The median age was 68 (IQR, 39-75) years, and 228 (53.4%) were men. SARS-CoV-2 spike-specific IgG saliva levels increased after 1 or 2 vaccine injections in individuals with previous infection and SARS-CoV-2-naive individuals. After vaccination, SARS-CoV-2-specific saliva IgA levels, normalized with respect to total IgA levels, were significantly higher in participants with previous infection, as compared with the most responsive mRNA-1273 (Moderna) recipients (median normalized levels, 155 × 10-5 vs 37 × 10-5 at day 29; 107 × 10-5 vs 54 × 10-5 at day 57; and 104 × 10-5 vs 70 × 10-5 at day 180 [P < .001]). In contrast, compared with day 1, spike-specific IgA levels in the BNT162b2-vaccinated SARS-CoV-2-naive group increased only at day 57 (36 × 10-5 vs 49 × 10-5 [P = .01]). Bona fide multimeric secretory IgA levels were significantly higher in individuals with previous infection compared with SARS-CoV-2-naive individuals after 2 antigenic stimulations (median optical density, 0.36 [IQR, 0.16-0.63] vs 0.16 [IQR, 0.10-0.22]; P < .001).
The findings of this cohort study suggest that mRNA vaccination was associated with mucosal immunity in individuals without prior SARS-CoV-2 infection, but at much lower levels than in previously infected individuals. Further studies are needed to determine the association between specific saliva IgA levels and prevention of infection or transmission.</abstract><cop>United States</cop><pub>American Medical Association</pub><pmid>38652471</pmid><doi>10.1001/jamanetworkopen.2024.8051</doi><orcidid>https://orcid.org/0000-0003-2097-9677</orcidid><orcidid>https://orcid.org/0000-0002-8830-4273</orcidid><orcidid>https://orcid.org/0000-0003-2773-7750</orcidid><orcidid>https://orcid.org/0000-0002-8182-3628</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2574-3805 |
| ispartof | JAMA network open, 2024-04, Vol.7 (4), p.e248051 |
| issn | 2574-3805 2574-3805 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11040412 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | 2019-nCoV Vaccine mRNA-1273 Adult Aged Antibodies, Viral - analysis Antibodies, Viral - blood BNT162 Vaccine Cohort analysis Cohort Studies COVID-19 - immunology COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - immunology Disease transmission Emerging diseases Female France Human health and pathology Humans Immunity, Mucosal - immunology Immunoglobulin A - analysis Immunoglobulin A - blood Immunoglobulin G - blood Immunology Infections Infectious diseases Life Sciences Male Middle Aged Online Only Original Investigation Saliva - immunology Santé publique et épidémiologie SARS-CoV-2 - immunology Severe acute respiratory syndrome coronavirus 2 Vaccination - methods Vaccinology |
| title | Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T23%3A51%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20and%20Salivary%20IgG%20and%20IgA%20Response%20After%20COVID-19%20Messenger%20RNA%20Vaccination&rft.jtitle=JAMA%20network%20open&rft.au=Gorochov,%20Guy&rft.date=2024-04-01&rft.volume=7&rft.issue=4&rft.spage=e248051&rft.pages=e248051-&rft.issn=2574-3805&rft.eissn=2574-3805&rft_id=info:doi/10.1001/jamanetworkopen.2024.8051&rft_dat=%3Cproquest_pubme%3E3141378304%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3141378304&rft_id=info:pmid/38652471&rfr_iscdi=true |